Urolithin A analog inhibits castration-resistant prostate cancer by targeting the androgen receptor and its variant, androgen receptor-variant 7

We investigated the efficacy of a small molecule ASR-600, an analog of Urolithin A (Uro A), on blocking androgen receptor (AR) and its splice variant AR-variant 7 (AR-V7) signaling in castration-resistant prostate cancer (CRPC). ASR-600 effectively suppressed the growth of AR+ CRPC cells by inhibiti...

Повний опис

Бібліографічні деталі

Автори:	Balaji Chandrasekaran, Ashish Tyagi, Uttara Saran, Venkatesh Kolluru, Becca V. Baby, Venkat R. Chirasani, Nikolay V. Dokholyan, Jyh M. Lin, Amandeep Singh, Arun K. Sharma, Murali K. Ankem, Chendil Damodaran
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Frontiers Media S.A. 2023-03-01
Серія:	Frontiers in Pharmacology
Предмети:	CRPC Androgen Receptor AR-Splice Variants N-terminal domain small molecule growth inhibition
Онлайн доступ:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1137783/full
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!